Efgartigimod treatment in gMG patients led to reduced glucocorticoid use, with 26% ceasing use and 66% reducing dosage by at least 1 mg/day after one year. The study observed a decrease in reliance on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback